Other languages Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
4.63 ^USD	-11.81%		-11.47%	-11.64%

30/04	Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
19/04	Lyra Therapeutics, Inc. Announces Board Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
Lyra Therapeutics, Inc. Announces Board Changes	20/04
Lyra Therapeutics Files $300 Million Mixed Shelf Offering	22/03
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Lyra Therapeutics, Inc Announces Appointment of Ronan O?Brien as Chief Legal Officer	16/23/16
Lyra Therapeutics Says Phase 2 Trial for Chronic Rhinosinusitis Treatment Meets Primary Endpoint	12/23/12
Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery	12/23/12
Lyra Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09
Lyra Therapeutics Jumps Premarket Following Insider Share Purchases	05/23/05
Insider Buy: Lyra Therapeutics	03/23/03
Insider Buy: Lyra Therapeutics	03/23/03
Lyra Therapeutics Closes $50 Million Private Placement	01/23/01
Lyra Therapeutics Launches $50 Million Private Placement; Shares Surge Pre-Bell	26/23/26
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
Lyra Therapeutics, Inc. Announces Commencement of Enrollment in ENLIGHTEN II	25/23/25
Lyra Therapeutics Names John Bishop CTO	28/23/28
Lyra Therapeutics, Inc. Announces Appointment of John Bishop as Chief Technology Officer	27/23/27
Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients	06/23/06
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/22/09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Other languages

Filters